Bulks list

The FDA bulks list framework (a 503A bulks list and a separate 503B bulks list) names the drug substances 503A pharmacies and 503B outsourcing facilities may use in compounding. A compounder generally may use a substance only if it is on the applicable bulks list, is the active ingredient in an FDA-approved drug, or appears on FDA's drug shortage list. The 2026 proposal to exclude semaglutide from the 503B bulks list and the parallel framework changes are central to current GLP-1 compounding enforcement.

How the bulks list framework works

Section 503A allows a state-licensed pharmacy to compound from a bulk drug substance if the substance is on the 503A bulks list, is a component of an FDA-approved drug, or appears on FDA's drug shortage list. Section 503B allows an outsourcing facility to compound from a bulk substance if the substance is on the 503B bulks list (narrower than the 503A list), is on FDA's drug shortage list, or meets the clinical-need exception FDA has set for certain categories. The two bulks lists are maintained separately and updated through formal FDA rulemaking with public comment.

The shortage list interaction is operationally significant: when a substance enters the shortage list, both 503A and 503B compounders may compound from it; when the substance is resolved off the shortage list, both lose that authority unless the substance is on the relevant bulks list. The transition produces a dispense-date defense framework: prescriptions dispensed during the shortage-list period are defensible; prescriptions dispensed after resolution may not be.

When the bulks list framework applies

The bulks list framework applies to every 503A and 503B compounding operation. The substance-by-substance analysis is required for every preparation. For 503A pharmacies, the bulks list analysis is conducted alongside the patient-specific prescription requirement and the USP compliance posture. For 503B facilities, the bulks list analysis intersects with the cGMP framework and the office-use compounding authority.

The compounder's exposure under bulks list violations

Compounding from a substance that is not on the applicable bulks list, not in an FDA-approved drug, and not on the shortage list violates the Federal Food, Drug, and Cosmetic Act. FDA exposure includes Form 483, Warning Letter, consent decree, injunction, criminal referral under the Park doctrine, and import alert for international manufacturers. Civil False Claims Act exposure attaches where the dispensed preparation supported government program claims. The defense framework focuses on the dispense-date analysis, the substance-status documentation, the clinical-significance exception analysis where the preparation differs from the commercial product, and the FDA enforcement defense at the Form 483 and Warning Letter stages.

Related terms

• 503A and 503B The two compounding pathways whose bulks lists drive most enforcement.
• GLP-1 The drug class central to current bulks list enforcement around semaglutide and tirzepatide.
• FDA Warning Letter The enforcement document that frequently cites bulks list violations.
• cGMP The 503B-side regulatory framework that operates alongside the 503B bulks list.

See also

• Practice area
  GLP-1 Compounding Defense

  The GLP-1 compounding defense framework focused on bulks list compliance and dispense-date analysis.

• Practice area
  Compounding Pharmacy Defense

  The compounding defense pillar spanning 503A, 503B, and the bulks list framework.